EverPoint Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

EverPoint Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-25,000	Closed	-$1.41M	–	526
2015 Q3	$1.41M	Sell	25,000 -325,000	-93%	-$21.1M	0.04%	350
2015 Q2	$20.7M	Buy	350,000 +100,000	+40%	+$6.17M	0.38%	67
2015 Q1	$15.6M	Buy	+250,000	New	+$14.5M	0.29%	105

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

EverPoint Asset Management's TEVA Position: Q1 2016 in Review

EverPoint Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 450,000 shares — an estimated $29.5M sold.

EverPoint Asset Management first reported a position in TEVA in Q2 2014 and held it in 7 quarters. The position peaked at $55M in Q2 2014. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

EverPoint Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
EverPoint Asset Management sold 450,000 Teva Pharmaceuticals shares in Q1 2016, an estimated $29.5M.
EverPoint Asset Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 7 quarters.
EverPoint Asset Management's Teva Pharmaceuticals position peaked at $55M in Q2 2014.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on EverPoint Asset Management's 13F filing for Q1 2016, filed 16 May 2016.